AtaiBeckley hits key antitrust milestones in Lilly deal
Rhea-AI Filing Summary
AtaiBeckley Inc. (ATAI) reports regulatory progress for its pending acquisition by Eli Lilly and Company under their July 15, 2026 Merger Agreement, under which Albali Acquisition Corporation will merge with and into AtaiBeckley, leaving AtaiBeckley as a wholly owned subsidiary of Eli Lilly.
The U.S. antitrust waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for the merger expired at 11:59 p.m. Eastern Time on August 28, 2026. The U.K. Competition and Markets Authority indicated on August 21, 2026 that it then had no further questions regarding the merger. The Australian Competition and Consumer Commission determined on August 27, 2026 that the merger may be consummated, subject to a 14‑calendar day waiting period scheduled to expire at 10:00 a.m. Eastern Time on September 10, 2026. The company highlights risks that the merger may be delayed or may not close, including potential failure to obtain stockholder approval or satisfy closing conditions.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
HSR waiting period expiration time: 11:59 p.m. Eastern Time on August 28, 2026
CMA feedback date: August 21, 2026
ACCC determination date: August 27, 2026
+3 more
6 metrics
HSR waiting period expiration time
11:59 p.m. Eastern Time on August 28, 2026
Expiration of the Hart-Scott-Rodino Act waiting period for the merger
CMA feedback date
August 21, 2026
Date the U.K. Competition and Markets Authority indicated it had no further questions
ACCC determination date
August 27, 2026
Date the Australian Competition and Consumer Commission determined the merger may be consummated
ACCC waiting period length
14 calendar days
Waiting period before the merger may be consummated in Australia
ACCC waiting period expiration time
10:00 a.m. Eastern Time on September 10, 2026
Scheduled expiration of the Australian waiting period tied to the merger
Merger Agreement date
July 15, 2026
Date AtaiBeckley Inc. and Eli Lilly and Company entered into the Merger Agreement
Key Terms
Hart-Scott-Rodino Antitrust Improvements Act of 1976, Competition and Markets Authority, Australian Competition and Consumer Commission, contingent value rights, +1 more
5 terms
Hart-Scott-Rodino Antitrust Improvements Act of 1976 regulatory
"The applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976"
Competition and Markets Authority regulatory
"the Competition and Markets Authority in the United Kingdom responded to a briefing paper"
The Competition and Markets Authority is an independent government regulator that enforces rules to keep markets competitive, reviews mergers, and investigates unfair business practices. Think of it as a referee for the economy: its decisions can block or change deals, impose fines, or force companies to change how they operate, which can directly affect a company’s value, deal certainty, and investors’ expectations about future profits.
Australian Competition and Consumer Commission regulatory
"the Australian Competition and Consumer Commission published its determination that the Merger may be consummated"
contingent value rights financial
"milestone payments pursuant to the contingent value rights to be paid to Company stockholders"
Contingent value rights are special financial instruments that give their holder the potential to receive additional payments if certain future events or conditions happen, such as the achievement of specific business milestones. They are like a promise of extra rewards that depend on how well a project or company performs later on. Investors care about them because they offer a chance for extra gains but also carry uncertainty, as the extra payments are not guaranteed.
forward-looking statements regulatory
"contains forward-looking statements that involve substantial risks and uncertainties"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What U.S. antitrust milestone did ATAI announce for its merger with Eli Lilly?
The U.S. Hart-Scott-Rodino antitrust waiting period for ATAI’s merger with Eli Lilly expired at 11:59 p.m. Eastern Time on August 28, 2026, satisfying a key U.S. antitrust timing requirement for the proposed transaction.
What was the U.K. Competition and Markets Authority’s position on ATAI’s merger?
On August 21, 2026, the U.K. Competition and Markets Authority responded to a briefing paper from Eli Lilly indicating that it had, at that time, no further questions related to the merger involving ATAI.
What determination did the Australian Competition and Consumer Commission make about the ATAI merger?
On August 27, 2026, the Australian Competition and Consumer Commission determined that ATAI’s merger may be consummated, subject to a 14‑calendar day waiting period expiring at 10:00 a.m. Eastern Time on September 10, 2026.
Is ATAI’s merger with Eli Lilly guaranteed to close?
No. ATAI discloses that there can be no assurance the merger will be consummated, citing risks including potential failure to obtain stockholder approval, regulatory clearances or satisfaction of other closing conditions.
What key risks to the ATAI merger does the company highlight?
ATAI lists risks such as stockholders not approving the Merger Agreement, failure or delay in receiving regulatory clearances, conditions to closing not being satisfied or waived, potential disruption to operations, and that milestone payments under contingent value rights may not become payable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
